Date: 2015-07-01
Type of information: Licensing agreement
Compound: CAP®Go technology
Company: CEVEC Pharmaceuticals (Germany) Biotest (Germany)
Therapeutic area: Technology - Services - Genetic diseases - Hematological diseases - Rare diseases
Type agreement: licensing
Action mechanism:
Disease: hemophilia
Details: * On July 1st, 2015, Cevec Pharmaceuticals announced that it has granted a license for its proprietary CAP®Go technology to Biotest AG for the development, production and commercialization of candidate molecules to treat the symptoms of hemophilia patients. Biotest AG is a provider of plasma proteins and biological drugs. The company develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma.
Financial terms: Under the terms of the license agreement, Cevec will receive service fees for ongoing development support, upfront and milestone payments as well as royalties on future product sales.
Latest news:
